{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:16:57Z","timestamp":1781878617409,"version":"3.54.5"},"reference-count":219,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondo Europeo de Desarrollo Regional (FEDER): Instituto de Salud Carlos III","award":["PI20\/00991"],"award-info":[{"award-number":["PI20\/00991"]}]},{"name":"Fondo Europeo de Desarrollo Regional (FEDER): Instituto de Salud Carlos III","award":["CP21\/00111"],"award-info":[{"award-number":["CP21\/00111"]}]},{"name":"Miguel Servet Program type I","award":["PI20\/00991"],"award-info":[{"award-number":["PI20\/00991"]}]},{"name":"Miguel Servet Program type I","award":["CP21\/00111"],"award-info":[{"award-number":["CP21\/00111"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Tumors are composed of a plethora of extracellular matrix, tumor and non-tumor cells that form a tumor microenvironment (TME) that nurtures the tumor cells and creates a favorable environment where tumor cells grow and proliferate. In multiple myeloma (MM), the TME is the bone marrow (BM). Non-tumor cells can belong either to the non-hematological compartment that secretes soluble mediators to create a favorable environment for MM cells to grow, or to the immune cell compartment that perform an anti-MM activity in healthy conditions. Indeed, marrow-infiltrating lymphocytes (MILs) are associated with a good prognosis in MM patients and have served as the basis for developing different immunotherapy strategies. However, MM cells and other cells in the BM can polarize their phenotype and activity, creating an immunosuppressive environment where immune cells do not perform their cytotoxic activity properly, promoting tumor progression. Understanding cell\u2013cell interactions in the BM and their impact on MM proliferation and the performance of tumor surveillance will help in designing efficient anti-MM therapies. Here, we take a journey through the BM, describing the interactions of MM cells with cells of the non-hematological and hematological compartment to highlight their impact on MM progression and the development of novel MM treatments.<\/jats:p>","DOI":"10.3390\/cancers14153796","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T21:52:48Z","timestamp":1659649968000},"page":"3796","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments"],"prefix":"10.3390","volume":"14","author":[{"given":"Rosario","family":"Herv\u00e1s-Salcedo","sequence":"first","affiliation":[{"name":"Department of Experimental Hematology, Instituto de Investigaci\u00f3n Sanitaria-Fundaci\u00f3n Jim\u00e9nez Diaz (IIS-FJD), University Autonomous of Madrid (UAM), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mart\u00edn-Antonio","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Instituto de Investigaci\u00f3n Sanitaria-Fundaci\u00f3n Jim\u00e9nez Diaz (IIS-FJD), University Autonomous of Madrid (UAM), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"717850","DOI":"10.3389\/fimmu.2021.717850","article-title":"Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner","volume":"12","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1038\/s41388-018-0341-x","article-title":"Molecular Alterations of Cancer Cell and Tumour Microenvironment in Metastatic Gastric Cancer","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jpi.12295","article-title":"Melatonin Set out to ER Stress Signaling Thwarts Epithelial Mesenchymal Transition and Peritoneal Dissemination via Calpain-Mediated C\/EBP\u03b2 and NF\u03baB Cleavage","volume":"60","author":"Wu","year":"2016","journal-title":"J. Pineal Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/onc.2013.238","article-title":"EphA2 Promotes Epithelial-Mesenchymal Transition through the Wnt\/\u03b2-Catenin Pathway in Gastric Cancer Cells","volume":"33","author":"Huang","year":"2014","journal-title":"Oncogene"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor Microenvironment Complexity and Therapeutic Implications at a Glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fimmu.2018.00070","article-title":"Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses","volume":"9","author":"Oliver","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"a026781","DOI":"10.1101\/cshperspect.a026781","article-title":"Tumor Microenvironment and Differential Responses to Therapy","volume":"7","author":"Hirata","year":"2017","journal-title":"Cold Spring Harb. Perspect Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The Tumor Microenvironment at a Glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature13541","article-title":"Endothelial-Cell FAK Targeting Sensitizes Tumours to DNA-Damaging Therapy","volume":"514","author":"Tavora","year":"2014","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Battram, A.M., Bachiller, M., and Mart\u00edn-Antonio, B. (2020). Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124346"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1101\/gad.284851.116","article-title":"A Senescence Secretory Switch Mediated by PI3K\/AKT\/MTOR Activation Controls Chemoprotective Endothelial Secretory Responses","volume":"30","author":"Bent","year":"2016","journal-title":"Genes Dev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.imbio.2015.11.010","article-title":"Tumor Associated Macrophages Provide the Survival Resistance of Tumor Cells to Hypoxic Microenvironmental Condition through IL-6 Receptor-Mediated Signals","volume":"222","author":"Jeong","year":"2017","journal-title":"Immunobiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1101\/gad.180331.111","article-title":"Macrophages and Cathepsin Proteases Blunt Chemotherapeutic Response in Breast Cancer","volume":"25","author":"Shree","year":"2011","journal-title":"Genes Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","article-title":"Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment","volume":"73","author":"Dijkgraaf","year":"2013","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-019-0362-2","article-title":"Cancer-Associated Fibroblasts in Radiotherapy: Challenges and New Opportunities","volume":"17","author":"Wang","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/0008-5472.CAN-17-0524","article-title":"Radiotherapy-Activated Cancer-Associated Fibroblasts Promote Tumor Progression through Paracrine IGF1R Activation","volume":"78","author":"Tommelein","year":"2018","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.canlet.2018.10.015","article-title":"Cancer-Associated Fibroblast (CAF)-Derived IL32 Promotes Breast Cancer Cell Invasion and Metastasis via Integrin \u03923-P38 MAPK Signalling","volume":"442","author":"Wen","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival","volume":"25","author":"Carstens","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.coi.2007.02.001","article-title":"Cancer Immunosurveillance, Immunoediting and Inflammation: Independent or Interdependent Processes?","volume":"19","author":"Bui","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed\/Refractory Malignancies","volume":"29","author":"Rives","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_24","first-page":"173","article-title":"Preclinical Development of a Humanized Chimeric Antigen Receptor against B Cell Maturation Antigen for Multiple Myeloma","volume":"106","author":"Castella","year":"2021","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Castella, M., Fern\u00e1ndez de Larrea, C., and Mart\u00edn-Antonio, B. (2018). Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113613"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortiz, A., Rodr\u00edguez-Garc\u00eda, Y., Encinas, J., Maroto-Mart\u00edn, E., Castellano, E., Teixid\u00f3, J., and Mart\u00ednez-L\u00f3pez, J. (2021). The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers, 13.","DOI":"10.3390\/cancers13020217"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_30","unstructured":"(2022, June 20). Bone Marrow Niches in Haematological Malignancies | Nature Reviews Cancer. Available online: https:\/\/www.nature.com\/articles\/s41568-020-0245-2."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/leu.2017.102","article-title":"Proteomic Characterization of Human Multiple Myeloma Bone Marrow Extracellular Matrix","volume":"31","author":"Glavey","year":"2017","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/sj.onc.1206315","article-title":"Cell Adhesion-Mediated Drug Resistance (CAM-DR) Is Associated with Activation of NF-\u039aB (RelB\/P50) in Myeloma Cells","volume":"22","author":"Landowski","year":"2003","journal-title":"Oncogene"},{"key":"ref_33","unstructured":"(2022, May 23). Targeting the Bone Marrow Microenvironment in Multiple Myeloma-Kawano-2015-Immunological Review-Wiley Online Library. Available online: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imr.12233."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3747\/co.21.1798","article-title":"Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations","volume":"21","author":"Kouroukis","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/ajh.25627","article-title":"Phase I\/II Trial of the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib as a Chemosensitization Strategy in Relapsed\/Refractory Multiple Myeloma","volume":"94","author":"Ghobrial","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a Model for the Process of Metastasis: Implications for Therapy","volume":"120","author":"Ghobrial","year":"2012","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09262","article-title":"Mesenchymal and Haematopoietic Stem Cells Form a Unique Bone Marrow Niche","volume":"466","author":"Michurina","year":"2010","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.blre.2005.11.002","article-title":"The Role of Mesenchymal Stem Cells in Haemopoiesis","volume":"20","author":"Dazzi","year":"2006","journal-title":"Blood Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding Multiple Myeloma Pathogenesis in the Bone Marrow to Identify New Therapeutic Targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0301-472X(02)00970-0","article-title":"Selective in Vivo Growth of Lymphocyte Function- Associated Antigen-1\u2013Positive Murine Myeloma Cells: Involvement of Function-Associated Antigen-1\u2013Mediated Homotypic Cell-Cell Adhesion","volume":"31","author":"Asosingh","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_41","first-page":"969","article-title":"Inhibition of Lymphocyte Function Associated Antigen 1 by LFA878 Induces Apoptosis in Multiple Myeloma Cells and Is Associated with Downregulation of the Focal Adhesion Kinase\/Phosphatidylinositol 3 Kinase\/Akt Pathway","volume":"31","author":"Schmidmaier","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma","volume":"9","author":"Harmer","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in Biology of Multiple Myeloma: Clinical Applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 MAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2169\/internalmedicine.50.4636","article-title":"Successful Treatment of a Patient with Rheumatoid Arthritis and IgA-\u03ba Multiple Myeloma with Tocilizumab","volume":"50","author":"Matsuyama","year":"2011","journal-title":"Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone Marrow Mesenchymal Stem Cells Are Abnormal in Multiple Myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00005-008-0022-5","article-title":"Abnormal Cytokine Production by Bone Marrow Stromal Cells of Multiple Myeloma Patients in Response to RPMI8226 Myeloma Cells","volume":"56","year":"2008","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e4855517","DOI":"10.1155\/2022\/4855517","article-title":"Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells","volume":"2022","author":"Deng","year":"2022","journal-title":"Stem Cells Int."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"(2022, May 23). BAFF and APRIL Protect Myeloma Cells from Apoptosis Induced by Interleukin 6 Deprivation and Dexamethasone | Blood | American Society of Hematology. Available online: https:\/\/ashpublications.org\/blood\/article\/103\/8\/3148\/18054\/BAFF-and-APRIL-protect-myeloma-cells-from.","DOI":"10.1182\/blood-2003-06-1984"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"(2022, May 23). Expression of BCMA, TACI, and BAFF-R in Multiple Myeloma: A Mechanism for Growth and Survival | Blood | American Society of Hematology. Available online: https:\/\/ashpublications.org\/blood\/article\/103\/2\/689\/17829\/Expression-of-BCMA-TACI-and-BAFF-R-in-multiple.","DOI":"10.1182\/blood-2003-06-2043"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"(2022, May 23). APRIL and BCMA Promote Human Multiple Myeloma Growth and Immunosuppression in the Bone Marrow Microenvironment | Blood | American Society of Hematology. Available online: https:\/\/ashpublications.org\/blood\/article\/127\/25\/3225\/35206\/APRIL-and-BCMA-promote-human-multiple-myeloma.","DOI":"10.1182\/blood-2016-01-691162"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-Based Chimeric Antigen Receptor for Dual Targeting of BCMA and TACI in Multiple Myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_54","unstructured":"(2022, May 23). The Role of Tumor Necrosis Factor \u03b1 in the Pathophysiology of Human Multiple Myeloma: Therapeutic Applications | Oncogene. Available online: https:\/\/www.nature.com\/articles\/1204623."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.ejca.2013.07.010","article-title":"Inhibition of the Tumour Necrosis Factor-Alpha Autocrine Loop Enhances the Sensitivity of Multiple Myeloma Cells to Anticancer Drugs","volume":"49","author":"Tsubaki","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V126.23.2954.2954","article-title":"Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma","volume":"126","author":"Calip","year":"2015","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: The First Interleukin-6-Receptor Inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB Multicentre Dose-Determination Study of BHQ880 in Combination with Anti-Myeloma Therapy and Zoledronic Acid in Patients with Relapsed or Refractory Multiple Myeloma and Prior Skeletal-Related Events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bone.2010.06.016","article-title":"Osteoblast Function in Myeloma","volume":"48","author":"Roodman","year":"2011","journal-title":"Bone"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Gau, Y.-C., Yeh, T.-J., Hsu, C.-M., Hsiao, S.Y., and Hsiao, H.-H. (2022). Pathogenesis and Treatment of Myeloma-Related Bone Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063112"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative Histology of Myeloma-Induced Bone Changes","volume":"52","author":"Charhon","year":"1982","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense Inhibition of Macrophage Inflammatory Protein 1-\u03b1 Blocks Bone Destruction in a Model of Myeloma Bone Disease","volume":"108","author":"Choi","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for Macrophage Inflammatory Protein (MIP)-1alpha and MIP-1beta in the Development of Osteolytic Lesions in Multiple Myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"(2022, May 23). Macrophage Inflammatory Protein-1\u03b1 Is an Osteoclastogenic Factor in Myeloma That Is Independent of Receptor Activator of Nuclear Factor \u039aB Ligand | Blood | American Society of Hematology. Available online: https:\/\/ashpublications.org\/blood\/article\/97\/11\/3349\/107426\/Macrophage-inflammatory-protein-1-is-an.","DOI":"10.1182\/blood.V97.11.3349"},{"key":"ref_66","unstructured":"(2022, May 23). Notch-Directed Microenvironment Reprogramming in Myeloma: A Single Path to Multiple Outcomes | Leukemia. Available online: https:\/\/www.nature.com\/articles\/leu20136."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in Bone Modeling and Remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-Cell Contact between Marrow Stromal Cells and Myeloma Cells via VCAM-1 and Alpha (4) Beta (1)-Integrin Enhances Production of Osteoclast-Stimulating Activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab Compared with Zoledronic Acid on PFS in Multiple Myeloma: Exploratory Results of an International Phase 3 Study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1007\/s12325-020-01395-x","article-title":"Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study\u2014Asian Subgroup Analysis","volume":"37","author":"Huang","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: Mechanism of Action and Clinical Outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"(2022, May 23). Myeloma Cells Block RUNX2\/CBFA1 Activity in Human Bone Marrow Osteoblast Progenitors and Inhibit Osteoblast Formation and Differentiation | Blood | American Society of Hematology. Available online: https:\/\/ashpublications.org\/blood\/article\/106\/7\/2472\/21687\/Myeloma-cells-block-RUNX2-CBFA1-activity-in-human.","DOI":"10.1182\/blood-2004-12-4986"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"(2022, May 23). Osteoprotegerin Is Bound, Internalized, and Degraded by Multiple Myeloma Cells | Blood | American Society of Hematology. Available online: https:\/\/ashpublications.org\/blood\/article\/100\/8\/3002\/106454\/Osteoprotegerin-is-bound-internalized-and-degraded.","DOI":"10.1182\/blood-2002-04-1190"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-A4 Integrin Antibody Suppresses the Development of Multiple Myeloma and Associated Osteoclastic Osteolysis","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood.V114.22.750.750","article-title":"A Phase I\/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)","volume":"114","author":"Padmanabhan","year":"2009","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000353312","article-title":"Angiogenesis in Multiple Myeloma","volume":"99","author":"Vacca","year":"2014","journal-title":"Angiogenes. Lymphangiogenes. Clin. Implic."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.ircmb.2014.10.004","article-title":"Multiple Myeloma as a Model for the Role of Bone Marrow Niches in the Control of Angiogenesis","volume":"314","author":"Ribatti","year":"2015","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20394","DOI":"10.18632\/oncotarget.14610","article-title":"Bone Marrow Micro-Environment Is a Crucial Player for Myelomagenesis and Disease Progression","volume":"8","author":"Mondello","year":"2017","journal-title":"Oncotarget"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_80","first-page":"2210","article-title":"Bone Marrow Angiogenesis in 400 Patients with Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, and Primary Amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_81","first-page":"706","article-title":"Hypoxia Inducible Factor-1 Alpha and Multiple Myeloma","volume":"4","author":"Bhaskar","year":"2016","journal-title":"Int. J. Adv. Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"(2022, May 24). Angiogenic Switch during 5T2MM Murine Myeloma Tumorigenesis: Role of CD45 Heterogeneity | Blood | American Society of Hematology. Available online: https:\/\/ashpublications.org\/blood\/article\/103\/8\/3131\/18020\/Angiogenic-switch-during-5T2MM-murine-myeloma.","DOI":"10.1182\/blood-2003-08-2946"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1158\/1078-0432.CCR-09-0040","article-title":"Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma","volume":"15","author":"Ria","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Summa, S.D., Vacca, A., and Ribatti, D. (2020). Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers, 12.","DOI":"10.3390\/cancers12113380"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0925-4773(00)00522-0","article-title":"Postnatal Vasculogenesis","volume":"100","author":"Ribatti","year":"2001","journal-title":"Mech. Dev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/leu.2016.3","article-title":"Targeting Vasculogenesis to Prevent Progression in Multiple Myeloma","volume":"30","author":"Moschetta","year":"2016","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10456-017-9571-8","article-title":"Endothelial Progenitor Cells in Multiple Myeloma Neovascularization: A Brick to the Wall","volume":"20","author":"Tenreiro","year":"2017","journal-title":"Angiogenesis"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e7954580","DOI":"10.1155\/2016\/7954580","article-title":"Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies","volume":"2016","author":"Reale","year":"2015","journal-title":"Stem. Cells Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fcvm.2018.00154","article-title":"It Takes Two: Endothelial-Perivascular Cell Cross-Talk in Vascular Development and Disease","volume":"5","author":"Sweeney","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular Endothelial Growth Factor and Interleukin-6 in Paracrine Tumor-Stromal Cell Interactions in Multiple Myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ria, R., Melaccio, A., Racanelli, V., and Vacca, A. (2020). Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061765"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2141.2011.08623.x","article-title":"Phase II Randomized Trial of Bevacizumab versus Bevacizumab and Thalidomide for Relapsed\/Refractory Multiple Myeloma: A California Cancer Consortium Trial","volume":"154","author":"Somlo","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/cncr.27745","article-title":"Results from AMBER, a Randomized Phase 2 Study of Bevacizumab and Bortezomib versus Bortezomib in Relapsed or Refractory Multiple Myeloma","volume":"119","author":"White","year":"2013","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hon.2043","article-title":"Sorafenib in Patients with Refractory or Recurrent Multiple Myeloma","volume":"31","author":"Yordanova","year":"2013","journal-title":"Hematol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cam4.276","article-title":"A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients with Relapsing and Resistant Multiple Myeloma: SWOG S0434","volume":"3","author":"Srkalovic","year":"2014","journal-title":"Cancer Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.leu.2403285","article-title":"Effect of Thalidomide Therapy on Bone Marrow Angiogenesis in Multiple Myeloma","volume":"18","author":"Kumar","year":"2004","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ijc.32125","article-title":"Effect of Induction Therapy with Lenalidomide, Doxorubicin and Dexamethasone on Bone Remodeling and Angiogenesis in Newly Diagnosed Multiple Myeloma","volume":"145","author":"Terpos","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jcyt.2018.10.006","article-title":"Exosome-Transmitted LINC00461 Promotes Multiple Myeloma Cell Proliferation and Suppresses Apoptosis by Modulating MicroRNA\/BCL-2 Expression","volume":"21","author":"Deng","year":"2019","journal-title":"Cytotherapy"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1535-7163.MCT-07-0311","article-title":"Zoledronic Acid Affects Over-Angiogenic Phenotype of Endothelial Cells in Patients with Multiple Myeloma","volume":"6","author":"Scavelli","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT Immune Checkpoint Blockade Restores CD8+ T-Cell Immunity against Multiple Myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive Transfer of Activated Marrow-Infiltrating Lymphocytes Induces Measurable Antitumor Immunity in the Bone Marrow in Multiple Myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/2326-6066.CIR-19-0115","article-title":"Metabolic Consequences of T-Cell Costimulation in Anticancer Immunity","volume":"7","author":"Teijeira","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T Cell Exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.1016\/j.bbmt.2017.12.359","article-title":"Enhanced Expression of CXCR4 Facilitates C-Kit-Targeted CAR-T Cell Trafficking to Bone Marrow and Enables Donor Stem Cell Engraftment","volume":"24","author":"Arai","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy Bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","article-title":"Immune Checkpoint Inhibitors for the Treatment of Myeloma: Novel Investigational Options","volume":"30","author":"Moreau","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.leukres.2004.06.003","article-title":"High Th1\/Th2 Ratio in Patients with Multiple Myeloma","volume":"29","author":"Ogawara","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2249.2001.01582.x","article-title":"Deregulated Cytokine Network and Defective Th1 Immune Response in Multiple Myeloma","volume":"125","author":"Frassanito","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical Activity and Determinants of Response of the GPRC5DxCD3 Bispecific Antibody Talquetamab in Multiple Myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-Cell Phenotypes Associated with Effective CAR T-Cell Therapy in Postinduction vs Relapsed Multiple Myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.2011.575","article-title":"The Frequency of T Regulatory Cells Modulates the Survival of Multiple Myeloma Patients: Detailed Characterisation of Immune Status in Multiple Myeloma","volume":"106","author":"Giannopoulos","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Feyler, S., Scott, G.B., Parrish, C., Jarmin, S., Evans, P., Short, M., McKinley, K., Selby, P.J., and Cook, G. (2012). Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035981"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of Regulatory T Cells in Cancer Immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 Overexpression in Multiple Myeloma Bone Marrow as a Sign of Accumulation of CD4+ T Regulatory Cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-021-01422-y","article-title":"Transient Regulatory T-Cell Targeting Triggers Immune Control of Multiple Myeloma and Prevents Disease Progression","volume":"36","author":"Dahlhoff","year":"2022","journal-title":"Leukemia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 Programs TH-17 Cell Differentiation by Promoting Sequential Engagement of the IL-21 and IL-23 Pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 Produced by TH17 Cells Promotes Myeloma Cell Growth and Inhibits Immune Function in Multiple Myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"107781","DOI":"10.1016\/j.intimp.2021.107781","article-title":"Interleukin-17 Induces Pyroptosis in Osteoblasts through the NLRP3 Inflammasome Pathway in Vitro","volume":"96","author":"Lei","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_121","first-page":"187","article-title":"Effects of Thalidomide on the Ratio of Th17 to Treg Cells in Peripheral Blood and Expression of IL-17 and IL-35 in Patients with Multiple Myeloma","volume":"26","author":"Zhao","year":"2018","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/leu.2015.228","article-title":"Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma","volume":"30","author":"Prabhala","year":"2016","journal-title":"Leukemia"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple Myeloma Causes Clonal T-Cell Immunosenescence: Identification of Potential Novel Targets for Promoting Tumour Immunity and Implications for Checkpoint Blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-Cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Arasanz, H., Zuazo, M., Bocanegra, A., Gato, M., Mart\u00ednez-Aguillo, M., Morilla, I., Fern\u00e1ndez, G., Hern\u00e1ndez, B., L\u00f3pez, P., and Alberdi, N. (2020). Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 12.","DOI":"10.3390\/cancers12020344"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Battram, A.M., Bachiller, M., Lopez, V., Fern\u00e1ndez de Larrea, C., Urbano-Ispizua, A., and Mart\u00edn-Antonio, B. (2021). IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15\/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers, 13.","DOI":"10.3390\/cancers13143534"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni.3665","article-title":"A Sestrin-Dependent Erk-Jnk-P38 MAPK Activation Complex Inhibits Immunity during Aging","volume":"18","author":"Lanna","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC Class I Chain-Related Protein A Antibodies and Shedding Are Associated with the Progression of Multiple Myeloma","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 Axis Modulates the Natural Killer Cell versus Multiple Myeloma Effect: A Therapeutic Target for CT-011, a Novel Monoclonal Anti\u2013PD-1 Antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Pazina, T., MacFarlane, A.W., Bernabei, L., Dulaimi, E., Kotcher, R., Yam, C., Bezman, N.A., Robbins, M.D., Ross, E.A., and Campbell, K.S. (2021). Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13020226"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/art.39295","article-title":"Inhibition of Natural Killer Cell Cytotoxicity by Interleukin-6: Implications for the Pathogenesis of Macrophage Activation Syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow Stromal Cells Induce B7-H1 Expression on Myeloma Cells, Generating Aggressive Characteristics in Multiple Myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Tamura, H., Ishibashi, M., Sunakawa-Kii, M., and Inokuchi, K. (2020). PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12040924"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/eji.201041037","article-title":"IL-1\u03b2 Regulates a Novel Myeloid-Derived Suppressor Cell Subset That Impairs NK Cell Development and Function","volume":"40","author":"Elkabets","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-15-1320","article-title":"Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment","volume":"75","author":"Ponzetta","year":"2015","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing Natural Killer Cells for the Treatment of Multiple Myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Bachiller, M., Battram, A.M., Perez-Amill, L., and Mart\u00edn-Antonio, B. (2020). Natural Killer Cells in Immunotherapy: Are We Nearly There?. Cancers, 12.","DOI":"10.3390\/cancers12113139"},{"key":"ref_138","first-page":"173ra23","article-title":"CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation","volume":"5","author":"Bosma","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory B Cell-Myeloma Cell Interaction Confers Immunosuppression and Promotes Their Survival in the Bone Marrow Milieu","volume":"7","author":"Zhang","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"11283","DOI":"10.18632\/oncotarget.2207","article-title":"Multiple Myeloma Cells Recruit Tumor-Supportive Macrophages through the CXCR4\/CXCL12 Axis and Promote Their Polarization toward the M2 Phenotype","volume":"5","author":"Beider","year":"2014","journal-title":"Oncotarget"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.leukres.2015.06.003","article-title":"The Novel Biomarker of Alternative Macrophage Activation, Soluble Mannose Receptor (SMR\/SCD206): Implications in Multiple Myeloma","volume":"39","author":"Andersen","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41419-019-2012-4","article-title":"CCL2 Promotes Macrophages-Associated Chemoresistance via MCPIP1 Dual Catalytic Activities in Multiple Myeloma","volume":"10","author":"Xu","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cDon\u2019t Eat Me\u201d Signal of CD47-SIRP\u03b1 in Hematological Malignancies, an in-Depth Review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.neo.2019.05.006","article-title":"Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo","volume":"21","author":"Opperman","year":"2019","journal-title":"Neoplasia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-Promoting Immune-Suppressive Myeloid-Derived Suppressor Cells in the Multiple Myeloma Microenvironment in Humans","volume":"121","author":"Whitehill","year":"2013","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1093\/oncolo\/oyac067","article-title":"Daratumumab Improves Depth of Response and Progression-Free Survival in Transplant-Ineligible, High-Risk, Newly Diagnosed Multiple Myeloma","volume":"27","author":"Jakubowiak","year":"2022","journal-title":"Oncologist"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1182\/blood.V128.22.5696.5696","article-title":"Results from Ongoing Phase 1\/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","volume":"128","author":"Htut","year":"2016","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1517\/14712598.2013.799130","article-title":"Immunologic Microenvironment and Personalized Treatment in Multiple Myeloma","volume":"13","author":"Rossi","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"606368","DOI":"10.3389\/fonc.2020.606368","article-title":"Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities","volume":"10","author":"Yamamoto","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"625199","DOI":"10.3389\/fonc.2020.625199","article-title":"Game of Bones: How Myeloma Manipulates Its Microenvironment","volume":"10","author":"Joseph","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer Immunoediting and Immune Dysregulation in Multiple Myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The Tumor Microenvironment and Its Role in Promoting Tumor Growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V98.1.23","article-title":"Blood Levels of Immune Cells Predict Survival in Myeloma Patients: Results of an Eastern Cooperative Oncology Group Phase 3 Trial for Newly Diagnosed Multiple Myeloma Patients","volume":"98","author":"Kay","year":"2001","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.704","article-title":"T Cells in Myeloma","volume":"21","author":"Raitakari","year":"2003","journal-title":"Hematol. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"850358","DOI":"10.3389\/fimmu.2022.850358","article-title":"Emerging Strategies in TCR-Engineered T Cells","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T Cell Senescence and CAR-T Cell Exhaustion in Hematological Malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Ab Rahman, A.S., Strother, R.M., and Paddison, J. (2022). New Zealand National Retrospective Cohort Study of Survival Outcomes of Patients with Metastatic Melanoma Receiving Immune-Checkpoint Inhibitors. Asia Pac. J. Clin. Oncol., 1\u20138.","DOI":"10.1111\/ajco.13801"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-Related Adverse Events and Anti-Tumor Efficacy of Immune Checkpoint Inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00280-015-2870-0","article-title":"Phase II Study of the Immune-Checkpoint Inhibitor Ipilimumab plus Dacarbazine in Japanese Patients with Previously Untreated, Unresectable or Metastatic Melanoma","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of Exhausted CD8+ T Cells Differentially Mediate Tumor Control and Respond to Checkpoint Blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T Cells in Multiple Myeloma Display Features of Exhaustion and Senescence at the Tumor Site","volume":"9","author":"Thangavadivel","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"100494","DOI":"10.1016\/j.ctarc.2021.100494","article-title":"Aging-Associated Immune System Changes in Multiple Myeloma: The Dark Side of the Moon","volume":"29","author":"Visram","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V97.2.483","article-title":"Autocrine Interleukin-6 Production and Highly Malignant Multiple Myeloma: Relation with Resistance to Drug-Induced Apoptosis","volume":"97","author":"Frassanito","year":"2001","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00018-009-0026-2","article-title":"The Development and Function of Regulatory T Cells","volume":"66","author":"Workman","year":"2009","journal-title":"Cell Mol. Life Sci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.coi.2008.04.008","article-title":"Regulatory T Cells and Treatment of Cancer","volume":"20","author":"Curiel","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Hadjiaggelidou, C., and Katodritou, E. (2021). Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194588"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Raja, K.R.M., Rihova, L., Zahradova, L., Klincova, M., Penka, M., and Hajek, R. (2012). Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047077"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T Regulatory Cells in Multiple Myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A Novel Role of IL-17\u2013Producing Lymphocytes in Mediating Lytic Bone Disease in Multiple Myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3324\/haematol.2014.105866","article-title":"The Bone Marrow of Myeloma Patients Is Steadily Inhabited by a Normal-Sized Pool of Functional Regulatory T Cells Irrespectiveof the Disease Status","volume":"99","author":"Foglietta","year":"2014","journal-title":"Haematologica"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3389\/fimmu.2017.01632","article-title":"Metabolism Controls the Balance of Th17\/T-Regulatory Cells","volume":"8","author":"Sun","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41375-020-0947-1","article-title":"MiR-21 Antagonism Abrogates Th17 Tumor Promoting Functions in Multiple Myeloma","volume":"35","author":"Rossi","year":"2021","journal-title":"Leukemia"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clml.2019.12.009","article-title":"A Unique Role of T Helper 17 Cells in Different Treatment Stages of Multiple Myeloma","volume":"20","author":"Ma","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic Cells Mediate the Induction of Polyfunctional Human IL17-Producing Cells (Th17-1 Cells) Enriched in the Bone Marrow of Patients with Myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12979-020-00187-9","article-title":"Role of Immune Cells in the Removal of Deleterious Senescent Cells","volume":"17","author":"Kale","year":"2020","journal-title":"Immun. Ageing"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20130783","article-title":"P53-Dependent Chemokine Production by Senescent Tumor Cells Supports NKG2D-Dependent Tumor Elimination by Natural Killer Cells","volume":"210","author":"Iannello","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","article-title":"Memory T Cells: Strategies for Optimizing Tumor Immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Protein Cell"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12979-020-0173-8","article-title":"Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging","volume":"17","author":"Thomas","year":"2020","journal-title":"Immun. Ageing"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.4049\/jimmunol.1500082","article-title":"Thymic Involution Perturbs Negative Selection Leading to Autoreactive T Cells That Induce Chronic Inflammation","volume":"194","author":"Coder","year":"2015","journal-title":"J. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cytogfr.2021.01.006","article-title":"Hallmarks of Aging and Immunosenescence: Connecting the Dots","volume":"59","author":"Rodrigues","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.3389\/fimmu.2020.604591","article-title":"Immunosenescence Study of T Cells: A Systematic Review","volume":"11","author":"Rodriguez","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e13028","DOI":"10.1111\/acel.13028","article-title":"Reversal of Epigenetic Aging and Immunosenescent Trends in Humans","volume":"18","author":"Fahy","year":"2019","journal-title":"Aging Cell"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.3390\/ijms160510267","article-title":"Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy","volume":"16","author":"Gao","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.4049\/jimmunol.1100978","article-title":"Reversible Senescence in Human CD4+CD45RA+CD27- Memory T Cells","volume":"187","author":"Azevedo","year":"2011","journal-title":"J. Immunol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3389\/fimmu.2019.02247","article-title":"Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention","volume":"10","author":"Aiello","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"eaaq1564","DOI":"10.1126\/scitranslmed.aaq1564","article-title":"TORC1 Inhibition Enhances Immune Function and Reduces Infections in the Elderly","volume":"10","author":"Mannick","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood-2010-09-310888","article-title":"Inhibition of MTOR Blocks the Anti-Inflammatory Effects of Glucocorticoids in Myeloid Immune Cells","volume":"117","author":"Weichhart","year":"2011","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells","volume":"67","author":"Meade","year":"2007","journal-title":"Cancer Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"101279","DOI":"10.1016\/j.smim.2019.06.002","article-title":"ILCs in Hematologic Malignancies: Tumor Cell Killers and Tissue Healers","volume":"41","author":"Blom","year":"2019","journal-title":"Semin. Immunol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Antonio, B., Su\u00f1e, G., Perez-Amill, L., Castella, M., and Urbano-Ispizua, A. (2017). Natural Killer Cells: Angels and Devils for Immunotherapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091868"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s40425-019-0739-1","article-title":"Extracellular NK Histones Promote Immune Cell Anti-Tumor Activity by Inducing Cell Clusters through Binding to CD138 Receptor","volume":"7","author":"Najjar","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA Class I, NKG2D, and Natural Cytotoxicity Receptors Regulate Multiple Myeloma Cell Recognition by Natural Killer Cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"100930","DOI":"10.1016\/j.tranon.2020.100930","article-title":"NK Cell Infiltration Is Associated with Improved Overall Survival in Solid Cancers: A Systematic Review and Meta-Analysis","volume":"14","author":"Nersesian","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/jclinpath-2016-203614","article-title":"Decreased CD161 Activating and Increased CD158a Inhibitory Receptor Expression on NK Cells Underlies Impaired NK Cell Cytotoxicity in Patients with Multiple Myeloma","volume":"69","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm1452","article-title":"Decidual NK Cells Regulate Key Developmental Processes at the Human Fetal-Maternal Interface","volume":"12","author":"Hanna","year":"2006","journal-title":"Nat. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3389\/fimmu.2019.01397","article-title":"Features of Human Decidual NK Cells in Healthy Pregnancy and During Viral Infection","volume":"10","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.immuni.2017.11.018","article-title":"Natural Killer Cells Promote Fetal Development through the Secretion of Growth-Promoting Factors","volume":"47","author":"Fu","year":"2017","journal-title":"Immunity"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3389\/fimmu.2019.00960","article-title":"Uterine Natural Killer Cells","volume":"10","author":"Sojka","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"607669","DOI":"10.3389\/fimmu.2021.607669","article-title":"How Do Uterine Natural Killer and Innate Lymphoid Cells Contribute to Successful Pregnancy?","volume":"12","author":"Huhn","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Shah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D.A., Cooper, L.J.N., Decker, W.K., Li, S., Robinson, S.N., and Sekine, T. (2013). Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076781"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/cdd.2014.120","article-title":"Transmissible Cytotoxicity of Multiple Myeloma Cells by Cord Blood-Derived NK Cells Is Mediated by Vesicle Trafficking","volume":"22","author":"Najjar","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.intimp.2018.12.007","article-title":"Regulatory B Cells in Inflammatory Diseases and Tumor","volume":"67","author":"Cai","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"e1180485","DOI":"10.1080\/2162402X.2016.1180485","article-title":"Tumor-Released Autophagosomes Induce IL-10-Producing B Cells with Suppressive Activity on T Lymphocytes via TLR2-MyD88-NF-\u039aB Signal Pathway","volume":"5","author":"Zhou","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1182\/blood-2019-128703","article-title":"Onset of Regulatory B Cells Occurs at Initial Stage of B Cell Dysfunction in Multiple Myeloma","volume":"134","author":"Zou","year":"2019","journal-title":"Blood"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages Are an Abundant Component of Myeloma Microenvironment and Protect Myeloma Cells from Chemotherapy Drug-Induced Apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/leu.2012.272","article-title":"PSGL-1\/Selectin and ICAM-1\/CD18 Interactions Are Involved in Macrophage-Induced Drug Resistance in Myeloma","volume":"27","author":"Zheng","year":"2013","journal-title":"Leukemia"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.7150\/jca.30102","article-title":"High Numbers of CD163+ Tumor-Associated Macrophages Correlate with Poor Prognosis in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage Polarization","volume":"79","author":"Murray","year":"2017","journal-title":"Annu. Rev. Physiol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"129348","DOI":"10.1172\/jci.insight.129348","article-title":"MiR-16 Regulates Crosstalk in NF-\u039aB Tolerogenic Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages","volume":"4","author":"Khalife","year":"2019","journal-title":"JCI Insight"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/leu.2017.193","article-title":"Therapeutic Effects of CSF1R-Blocking Antibodies in Multiple Myeloma","volume":"32","author":"Wang","year":"2018","journal-title":"Leukemia"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e003975","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-Associated Macrophages in Multiple Myeloma: Advances in Biology and Therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J Immunother. Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid Derived Suppressor Cells Are Numerically, Functionally and Phenotypically Different in Patients with Multiple Myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.18632\/oncotarget.3300","article-title":"Multiple Myeloma Induces Mcl-1 Expression and Survival of Myeloid-Derived Suppressor Cells","volume":"6","author":"Lub","year":"2015","journal-title":"Oncotarget"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00262-016-1861-2","article-title":"Circulating Immune Cell Phenotype Can Predict the Outcome of Lenalidomide plus Low-Dose Dexamethasone Treatment in Patients with Refractory\/Relapsed Multiple Myeloma","volume":"65","author":"Lee","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"43992","DOI":"10.18632\/oncotarget.6083","article-title":"The Bone Marrow Microenvironment Enhances Multiple Myeloma Progression by Exosome-Mediated Activation of Myeloid-Derived Suppressor Cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"760382","DOI":"10.3389\/fonc.2021.760382","article-title":"Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma","volume":"11","author":"Uckun","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-Derived Suppressor Cells as Immunosuppressive Regulators and Therapeutic Targets in Cancer","volume":"6","author":"Li","year":"2021","journal-title":"Sig. Transduct. Target. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/15\/3796\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:04:04Z","timestamp":1760141044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/15\/3796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":219,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cancers14153796"],"URL":"https:\/\/doi.org\/10.3390\/cancers14153796","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}